Journal of Cancer Clinical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Mini Review - Journal of Cancer Clinical Research (2023) Volume 6, Issue 3

The Hidden Threat: Pathogen-Related Cancers

Yang Liu*

Department of Thoracic Oncology, Sichuan University china

*Corresponding Author:
Yang Liu
Department of Thoracic Oncology
Sichuan University
china
E-mail:yang@liu.cn

Received:25-Aug-2023, Manuscript No. AACCR-23-112249; Editor assigned:28-Aug-2023, PreQC No. AACCR-23-112249(PQ); Reviewed:11-Sep-2023, QC No. AACCR-23-112249; Revised:18-Sep-2023, Manuscript No. AACCR-23-112249(R); Published:25-Sep-2023, DOI:10.35841/ aaccr-6.3.156

Citation: Liu Y. The hidden threat: Pathogen-Related cancers. J Can Clinical Res. 2023; 6(3):156

Visit for more related articles at Journal of Cancer Clinical Research

Introduction

Cancer has long been considered one of the most formidable challenges to human health. It is a disease that can strike anyone, irrespective of age, gender, or ethnicity, and has the potential to wreak havoc on individuals and communities alike. While we have made significant progress in understanding and combating cancer, a lesser-known but equally insidious subset of this disease remains a concern: pathogen-related cancers. In this commentary, we will explore the fascinating yet alarming connection between certain pathogens and the development of cancer. Pathogens, such as bacteria, viruses, and parasites, have been responsible for many diseases throughout human history. We are well acquainted with their ability to cause infections like the common cold, tuberculosis, and malaria. However, what is less known is that some of these microorganisms can also contribute to the development of cancer [1].

Viruses are among the most notorious culprits in this regard. Human papillomavirus (HPV), for example, has been linked to cervical, anal, and oropharyngeal cancers. Hepatitis B and C viruses can lead to liver cancer, while Epstein-Barr virus (EBV) has connections to Hodgkin's lymphoma and nasopharyngeal carcinoma. These viruses may remain dormant for years before triggering cancer, making early detection and prevention challenging. Bacterial infections are not to be underestimated either. Helicobacter pylori, which infects the stomach lining, is associated with gastric cancer. Chronic inflammation caused by the bacterium can lead to mutations in the cells of the stomach lining, ultimately increasing the risk of cancer. Similarly, the bacterium Streptococcus gallolyticus has been linked to colon cancer. Understanding how pathogens contribute to cancer is a complex puzzle. In many cases, these microorganisms provoke chronic inflammation, which, over time, can cause DNA damage and genetic mutations in affected cells. Additionally, some viruses can directly integrate their DNA into the host cell's genome, disrupting normal cellular functions and promoting uncontrolled cell growth—a hallmark of cancer. Furthermore, pathogen-related cancers often carry distinct clinical and molecular characteristics. For instance, HPV-associated cervical cancer tends to affect younger individuals and has unique genetic markers compared to non-HPV-related cervical cancer. These differences can have significant implications for diagnosis, treatment, and prognosis.The recognition of the connection between pathogens and cancer has led to remarkable advances in cancer prevention and treatment. Vaccines, such as the HPV vaccine, have been developed to protect against certain viral infections that can lead to cancer. Widespread vaccination campaigns have already shown promising results in reducing the incidence of HPV-related cancers., Additionally, research into the mechanisms by which pathogens contribute to cancer has opened up new avenues for targeted therapies. Drugs that target specific viral or bacterial proteins involved in cancer development are currently being investigated as potential treatments for pathogen-related cancers. These therapies hold the promise of greater precision and fewer side effects compared to traditional cancer treatments [2].

Pathogen-related cancers are a sobering reminder that the battle against cancer is far from over. While we have made tremendous progress in understanding and treating this complex disease, the role of infectious agents in its development remains a pressing concern. Efforts to prevent and treat pathogen-related cancers are crucial not only for individual patients but also for public health as a whole. The intersection of infectious diseases and cancer serves as a testament to the intricate relationship between human health and the microorganisms that share our world. As we continue to unravel the mysteries of this connection, we move one step closer to a future where cancer, in all its forms, becomes a preventable and treatable condition. Until then, awareness, vaccination, and ongoing research are our best weapons in the fight against pathogen-related cancers [3].

In the relentless battle against cancer, there exists a subset of this formidable disease that hides in plain sight, driven by insidious agents from the microbial world. These silent culprits, known as pathogens, encompass viruses, bacteria, and parasites, and they have forged a clandestine alliance with cancer, leading to the emergence of what is commonly referred to as "pathogen-related cancers." While we have made great strides in our understanding of cancer's multifaceted nature, the intricate relationship between these hidden invaders and the development of malignancies remains a profound and underexplored realm of concern [4].

Pathogen-related cancers present a unique challenge to both the medical community and society at large. Unlike some cancers that primarily result from genetic mutations or environmental exposures, these malignancies are a testament to the intricate interplay between our own cells and the microbial agents that infiltrate them. This commentary delves into the intricate landscape of pathogen-related cancers, shedding light on the mechanisms, risk factors, and potential avenues for prevention and intervention in this often-overlooked realm of oncology [5].

References

  1. Tornesello ML, Buonaguro L, Buonaguro FM. An overview of new biomolecular pathways in pathogen-related cancers . Future Oncol. 2015;11(11):1625-39.

    2. Indexed at, Google Scholar,Cross Ref

  2. Kato T, Ueda Y, Kinoh H, et al. Pathogen-related signal transduction pathways of dendritic cells: perspectives for cancer immunotherapy. Curr Signal Transduct Ther. 2008;3(2):133-7.

    3. Indexed at, Google Scholar, Cross Ref

  3. Djomkam Zune AL, Olwal CO, Tapela K, et al. Pathogen-induced epigenetic modifications in cancers: implications for prevention, detection and treatment of cancers in Africa. Cancers. 2021;13(23):6051.

    4. Indexed at, Google Scholar, Cross Ref

  4. Darwiche R, Mène-Saffrané L, Gfeller D, et al. The pathogen-related yeast protein Pry1, a member of the CAP protein superfamily, is a fatty acid-binding proteins. J Biol Chem. 2017;292(20):8304-14.

    5. Indexed at, Google Scholar, Cross Ref

  5. Choudhary V, Darwiche R, Gfeller D, et al. The caveolin-binding motif of the pathogen-related yeast protein Pry1, a member of the CAP protein superfamily, is required for in vivo export of cholesteryl acetate.. J Lipid Res. 2014;55(5):883-94.

    6. Indexed at, Google Scholar, Cross Ref

Get the App